Sort   by:  
 Page size 
UnknownNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Not available
S-EPMC5019749 | biostudies-literature
UnknownNivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Not available
S-EPMC6075855 | biostudies-literature
UnknownMajor Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Not available
S-EPMC5877802 | biostudies-literature
UnknownSingle-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Not available
S-EPMC5757691 | biostudies-literature
UnknownNivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Not available
S-EPMC5541855 | biostudies-literature
UnknownNivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Not available
S-EPMC10589773 | biostudies-literature
UnknownInternational Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Not available
S-EPMC5834038 | biostudies-literature
Sort   by:  
 Page size